NYSE:IQV

IQVIA (IQV) Stock Price, News & Analysis

IQVIA logo
$245.68 -4.87 (-1.94%)
Closing price 03:59 PM Eastern
Extended Trading
$245.74 +0.06 (+0.03%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About IQVIA Stock (NYSE:IQV)

Advanced

Key Stats

Today's Range
$245.25
▼
$252.28
50-Day Range
$250.21
▼
$279.47
52-Week Range
$154.50
▼
$284.50
Volume
1.23 million shs
Average Volume
1.67 million shs
Market Capitalization
$40.49 billion
P/E Ratio
29.85
Dividend Yield
N/A
Price Target
$294.21
Consensus Rating
Moderate Buy

Company Overview

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products.

The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations. IQVIA was formed through the 2016 merger of Quintiles and IMS Health and adopted the IQVIA name in 2017.

Headquartered in Durham, North Carolina, IQVIA serves clients around the world. Ari Bousbib has led the company as chairman and chief executive officer since its formation.

AI Generated. May Contain Errors.

IQVIA Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

IQV MarketRank™: 
4.018896343965 of 5 stars

IQVIA scored higher than 80% of companies evaluated by MarketBeat, and ranked 76th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IQVIA has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 16 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    IQVIA has a consensus price target of $294.21, representing about 18.2% upside from its current price of $248.91.

  • Amount of Analyst Coverage

    IQVIA has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about IQVIA's stock forecast and price target.
  • Earnings Growth

    Earnings for IQVIA are expected to grow by 9.71% in the coming year, from $11.53 to $12.65 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IQVIA is 30.24, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.39.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IQVIA is 30.24, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.64.

  • Price to Earnings Growth Ratio

    IQVIA has a PEG Ratio of 2.29. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IQVIA has a P/B Ratio of 6.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about IQVIA's valuation and earnings.
  • Percentage of Shares Shorted

    1.88% of the float of IQVIA has been sold short.
  • Short Interest Ratio / Days to Cover

    IQVIA has a short interest ratio ("days to cover") of 2.08, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IQVIA has recently increased by 1.66%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    IQVIA does not currently pay a dividend.

  • Dividend Growth

    IQVIA does not have a long track record of dividend growth.

  • News Sentiment

    IQVIA has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for IQVIA this week, compared to 6 articles on an average week.
  • Search Interest

    13 people have searched for IQV on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added IQVIA to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IQVIA insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,936,907.00 in company stock.

  • Percentage Held by Insiders

    1.70% of the stock of IQVIA is held by insiders.

  • Percentage Held by Institutions

    89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IQVIA's insider trading history.
Receive IQV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IQV Stock News Headlines

Several months later, in early 2024, the league sent
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
ETFs Are Net Sellers of IQVIA (IQV) on Nov. 13
IQVIA: 3 Key Takeaways for Long-Term Investors
See More Headlines

IQV Stock Analysis - Frequently Asked Questions

IQVIA's stock was trading at $225.40 at the start of the year. Since then, IQV shares have increased by 10.4% and is now trading at $248.9080.

IQVIA Holdings Inc. (NYSE:IQV) issued its quarterly earnings data on Tuesday, October, 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.26 by $0.08. The business's revenue for the quarter was up 8.0% on a year-over-year basis.
Read the conference call transcript
.

IQVIA's Board of Directors initiated a stock repurchase plan on Thursday, May 7th 2026, which permits the company to buy back $2 billion in shares, according to EventVestor. This means that the company could repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board of directors believes its stock is undervalued.

IQVIA subsidiaries include Q2 Solutions, Linguamatics, Advanced Health Media LLC, DrugDev, Aileron Solutions, Novella Clinical LLC, 159 Solutions LLC, and more.

IQVIA (IQV) raised $900 million in an initial public offering on Thursday, May 9th 2013. The company issued 23,684,210 shares at a price of $36.00-$40.00 per share.

Top institutional investors of IQVIA include State Street Corp (4.56%), Boston Partners (2.65%), Goldman Sachs Group Inc. (0.88%) and American Century Companies Inc. (0.52%). Insiders that own company stock include Ari Bousbib, Eric Sherbet, W Richard Staub, James G Berkshire, Kevin C Knightly, Keriann Cherofsky, Bhavik Patel and John G Danhakl.
View institutional ownership trends
.

Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IQVIA investors own include NVIDIA (NVDA), Salesforce (CRM), PayPal (PYPL), Tesla (TSLA), Walt Disney (DIS), Adobe (ADBE) and Visa (V).

Company Calendar

Last Earnings
10/27/2026
Today
11/20/2026
Investor Day 2026
12/01/2026
Fiscal Year End
12/31/2026
Next Earnings (Estimated)
2/04/2027

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:IQV
CIK
1478242
Fax
N/A
Employees
93,000
Year Founded
2016

Price Target and Rating

High Price Target
$346.00
Low Price Target
$200.00
Potential Upside/Downside
+19.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
21 Analysts

Profitability

EPS (Trailing Twelve Months)
$8.23
Trailing P/E Ratio
29.85
Forward P/E Ratio
19.42
P/E Growth
2.29
Net Income
$1.36 billion
Net Margins
8.05%
Pretax Margin
8.97%
Return on Equity
30.02%
Return on Assets
6.52%

Debt

Debt-to-Equity Ratio
2.18
Current Ratio
0.83
Quick Ratio
0.83

Sales & Book Value

Annual Sales
$16.31 billion
Price / Sales
2.48
Cash Flow
$17.03 per share
Price / Cash Flow
14.43
Book Value
$41.21 per share
Price / Book
5.96

Miscellaneous

Outstanding Shares
164,800,000
Free Float
161,998,000
Market Cap
$40.49 billion
Optionable
Optionable
Beta
1.16

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NYSE:IQV) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners